# EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

> **NCT00821717** · PHASE3 · TERMINATED · sponsor: **Vifor Pharma** · enrollment: 35 (actual)

## Conditions studied

- Chronic Heart Failure
- Iron Deficiency
- Iron Deficiency Anemia
- Anaemia

## Interventions

- **DRUG:** Ferinject ® (Ferric carboxymaltose)
- **DRUG:** Normal saline (0.9%)

## Key facts

- **NCT ID:** NCT00821717
- **Lead sponsor:** Vifor Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2009-10
- **Final completion:** 2011-01
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Positive FAIR-HF study data are available, this study is identical as EFFICACY-HF. Due to low recruitment in EFFICACY-HF the decision was made to terminate it.
- **Last updated:** 2015-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00821717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00821717, "EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00821717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*